6 August 2025 - Around 2,100 people with advanced womb cancer are set to benefit from a groundbreaking new treatment option, following our recommendation of pembrolizumab (Keytruda) in final draft guidance published today.

The approval marks the first time immunotherapy has been combined with chemotherapy as a first-line treatment for the whole group of patients with primary advanced or recurrent endometrial cancer.

Read NICE press release